The markets traded mixed during the midday with the Dow rising 21 points to 17,429 as consumer sentiment slipped. Nasdaq lost 11 points to 5,022.
On the upside
Second quarter earnings and revenue rose for FibroGen (Nasdaq: FGEN).
KemPharm (Nasdaq: KMPH) reported positive data from an intranasal clinical trial of KP201/APAP.
Goldman Sachs added Kinder Morgan (NYSE: KMI) to its Conviction Buy List.
On the downside
King Digital Entertainment (NYSE: KING) reported lower second quarter earnings and revenue and forecast current quarter bookings below estimates.
Third quarter revenue fell short of expectations for Applied Materials (Nasdaq: AMAT) and the company forecast current quarter earnings below estimates.
xG Technology (Nasdaq: XGTI) priced its public offering of 2.55 million shares of Class A Units at the discounted price of $1 per unit.
In the broad market, advancing issues outpaced decliners by a margin of more than 9 to 7 on the NYSE and by nearly 10 to 9 on Nasdaq. The broader S&P 500 rose 3 points to 2,087. Bitcoin added $2 to $264.